Prof. Reiner Siebert is a Human Geneticist pioneering the genomic profiling and sequence analysis of B-cell lymphomas at the Institute of Human Genetics of the Christian-Albrechts-Universität zu Kiel (Germany). He was invited by Dr. Elías Campo, head of the Human and experimental functional oncomorphology IDIBAPS team and Director of Research at the Hospital Clínic of Barcelona, to offer an IDIBAPS Seminar held on May 6th. Dr. Iñaki Martín – Subero, investigator from Dr. Campo’s team and a former student at Prof. Siebert’s laboratory, introduced this crowded seminar.
Posts Tagged ‘Elias Campo’
Spanish Consortium for the Study of the Genome of the Chronic Lymphatic Leukemia, co-led by Dr. Elías Campo, links for the first time cancer with errors in the protection of chromosomes
A research published by Nature Genetics explores a new mechanism that may contribute to the development of diverse tumors, including chronic lymphatic leukemia, a form of cancer that affects thousands of new patients each year in Spain. The researchers have detected for the first time in a human cancer the mutation of an essential gene for the protection of the telomeres, situated on the edges of the chromosomes. The research, directed by Carlos López-Otín, of the University Institute of Oncology of the University of Oviedo, Elías Campo, of the Clínic Hospital/University of Barcelona, and María Blasco, director of the National Center of Oncological Research (CNIO), breaks new ground for the Spanish Consortium for the Study of the Genome of the Chronic Lymphatic Leukemia.
IDIBAPS investigators describe the genetic profile of an uncommon subtype of mantle cell lymphoma improving its proper diagnosis
Mantle cell lymphoma (MCL)is a subtype of B-cell lymphoma that comprises about 6-7% of all non-Hodgkin’s lymphoma cases. The main biomarker of this usually aggressive lymphoma is an alteration in Cyclin D1 expression. An article led by IDIBAPS investigators, and published in Blood(1), characterizes a new subtype of MCLs in which Cyclin D1 expression is not altered and offers clues to close different controversies about the genetics of the disease. Dr. Itziar Salaverria is the first author of the article, while the Miguel Servet investigator Dr. Sílvia Beà is the last one, both from the Human and experimental functional oncomorphology IDIBAPS team led by Dr. Elías Campo. Due to its significance, the article was highlighted by its editors as one of the “hottest” manuscripts to the media and selected for a comment (2) in the last issue of the Blood magazine.
2012 is ending, a difficult year also for science due to the crisis affecting much of the world. Despite this, it’s not all are bad news. The spanish researchers continue making relevant contributions to the international scientific scene. The website Materia made a top five of the Spanish scientific initiatives of the past year. In this ranking, there are three studies involving professionals from the Hospital Clínic and the IDIBAPS.
Dr. Elías Campo comments for Nature Genetics two innovative works about the genomics of Burkitt lymphoma
Burkitt lymphoma is an aggressive B-cell neoplasm initially recognized by Dennis Burkitt, a prescient surgeon working in Uganda in the middle years of the last century. Two studies in the last issue of Nature Genetics identify the landscape of somatic mutations in Burkitt lymphoma and highlight the pathogenic and clinical relevance of inactivating mutations of ID3. Dr. Elías Campo, Research Director of the Hospital Clínic of Barcelona and Director of the Fundació Clínic, writes a news article in the same issue about this two works, in a section called News and Views. The IDIBAPS team he leads, Human and experimental functional oncomorphology, knows well about genetics of such diseases, as he is the co-director of the Chronic Lymphocytic Leukemia (CLL) Genome Project.
The study, published today in Nature Genetics, represents a new perspective on cancer research, integrating the results of the complete sequencing of the genome and epigenome of patients with leukemia. Researchers identify the cells that cause the disease, discovered new molecular mechanisms involved in its development and improve its diagnosis.
The research is part of the Chronic Lymphocytic Leukemia Genome Spanish Consortium, with the participation of researchers from the BLUEPRINT European Consortium for the study of the epigenome. During the past two years this consortium, which is part of the International Cancer Genome Consortium, has published two works in the journals Nature and Nature Genetics that allowed the characterization of the genetic map of mutations associated with the disease.